Foghorn Therapeutics Announces FDA Has Placed A Clinical Hold On Phase I Dose Escalation Study Of FHD-286
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system,